Slingshot members are tracking this event:

Tensha Therapeutics To Be Acquired By Roche

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Under the terms of the agreement, Tensha’s shareholders will receive an upfront cash payment of $115 million, plus additional contingent payments of up to $420 million based on the achievement of certain predetermined clinical and regulatory milestones. The transaction is subject to customary closing conditions and anticipated to close in the first quarter of 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ten-010, Phase 1b, Acquisition, Transaction, Cancer Therapeutics, Solid And Hematological Tumors, Bet Biology